Breaking News, Collaborations & Alliances

Samsung Biologics Signs Deal with Kanaph Therapeutics

To develop treatment for retinal diseases.

By: Contract Pharma

Contract Pharma Staff

Samsung Biologics and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.   According to Kanaph Therapeutics, KNP-301 is designed to target autoimmune diseases by inhibiting the alternative pathway of the complement system. With the benefits of its bi-specific approach, it aims to successfully treat complement-mediated and angiogenesis driven retinal diseases by suppressing both C3b and VEGF simulta...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters